The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan ; volume:44 ; number:6 ; day:27 ; month:5 ; year:2021 ; pages:711-722 ; date:6.2021
Drug safety ; 44, Heft 6 (27.5.2021), 711-722, 6.2021
- Creator
-
Yamaoka, Kunihiro
Tanaka, Yoshiya
Kameda, Hideto
Khan, Nasser
Sasaki, Nobuhito
Harigai, Masayoshi
Song, Yanna
Zhang, Ying
Takeuchi, Tsutomu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40264-021-01067-x
- URN
-
urn:nbn:de:101:1-2021093020394746425460
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamaoka, Kunihiro
- Tanaka, Yoshiya
- Kameda, Hideto
- Khan, Nasser
- Sasaki, Nobuhito
- Harigai, Masayoshi
- Song, Yanna
- Zhang, Ying
- Takeuchi, Tsutomu
- SpringerLink (Online service)
Other Objects (12)
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Vergleich der Verkehrsentwicklung in deutschen Großstädten und Shanghai sowie Herleitung von Handlungserfordernissen
Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Vergleich der Verkehrsentwicklung in deutschen Großstädten und Shanghai sowie Herleitung von Handlungserfordernissen
Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Rheumatoid arthritis
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Genome-oriented treatment strategies for autoimmune diseases
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Usefulness of nailfold videocapillaroscopy for systemic sclerosis
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Vergleich der Verkehrsentwicklung in deutschen Großstädten und Shanghai sowie Herleitung von Handlungserfordernissen
Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis